Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) EBIT (2022 - 2026)

Sagimet Biosciences' EBIT history spans 5 years, with the latest figure at -$11.7 million for Q1 2026.

  • Quarterly EBIT rose 41.04% to -$11.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$48.7 million through Mar 2026, up 25.65% year-over-year, with the annual reading at -$56.9 million for FY2025, 4.47% down from the prior year.
  • EBIT came in at -$11.7 million for Q1 2026, down from -$10.8 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$6.8 million in Q1 2023 to a low of -$19.9 million in Q1 2025.
  • The 5-year median for EBIT is -$10.0 million (2023), against an average of -$11.0 million.
  • Year-over-year, EBIT tumbled 126.81% in 2024 and then soared 41.04% in 2026.
  • Sagimet Biosciences' EBIT stood at -$7.4 million in 2022, then decreased by 28.13% to -$9.5 million in 2023, then crashed by 92.21% to -$18.2 million in 2024, then soared by 40.84% to -$10.8 million in 2025, then fell by 8.81% to -$11.7 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's EBIT are -$11.7 million (Q1 2026), -$10.8 million (Q4 2025), and -$14.3 million (Q3 2025).